Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
25.80
-0.14 (-0.54%)
At close: Apr 2, 2026, 4:00 PM EDT
25.96
+0.16 (0.62%)
After-hours: Apr 2, 2026, 7:27 PM EDT
Zymeworks Revenue
In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth. Zymeworks had revenue of $2.52M in the quarter ending December 31, 2025, a decrease of -91.90%.
Revenue (ttm)
$105.97M
Revenue Growth
+38.87%
P/S Ratio
17.96
Revenue / Employee
$401,383
Employees
264
Market Cap
1.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Soleno Therapeutics | 190.41M |
| Stoke Therapeutics | 184.42M |
| Viridian Therapeutics | 70.85M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 51.95M |
| Capricor Therapeutics | 11.13M |
ZYME News
- 3 days ago - Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewsWire
- 5 days ago - Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate - GlobeNewsWire
- 11 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting - GlobeNewsWire
- 17 days ago - Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting - GlobeNewsWire
- 4 weeks ago - Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside - Seeking Alpha
- 4 weeks ago - Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing - GlobeNewsWire